Verastem Updates Corporate Presentation with Latest Insights
PremiumCompany AnnouncementsVerastem Updates Corporate Presentation with Latest Insights
30d ago
Verastem partner GenFleet says China’s NMPA approved clinical trial application
PremiumThe Fly
Verastem partner GenFleet says China’s NMPA approved clinical trial application
1M ago
Verastem price target lowered to $20 from $34 at Alliance Global Partners
PremiumThe Fly
Verastem price target lowered to $20 from $34 at Alliance Global Partners
2M ago
Verastem reports Q1 adjusted EPS (98c), consensus ($1.03)
PremiumThe FlyVerastem reports Q1 adjusted EPS (98c), consensus ($1.03)
3M ago
VSTM Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
VSTM Upcoming Earnings Report: What to Expect?
3M ago
Verastem names John Hayslip as Chief Medical Officer
PremiumThe Fly
Verastem names John Hayslip as Chief Medical Officer
3M ago
Verastem reports Q4 adjusted EPS ($1.10), consensus (62c)
PremiumThe FlyVerastem reports Q4 adjusted EPS ($1.10), consensus (62c)
4M ago
Verastem receives Orphan Drug Designation from FDA for avutometinib
PremiumThe Fly
Verastem receives Orphan Drug Designation from FDA for avutometinib
5M ago
Verastem treatment of low grade serous ovarian cancer granted orphan designation
PremiumThe Fly
Verastem treatment of low grade serous ovarian cancer granted orphan designation
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100